4-Aminobiphenyl (ABP), a prototypical aromatic
amine carcinogen in rodents and humans, requires bioactivation to manifest its toxic effects. A traditional model of ABP bioactivation, based on in vitro
enzyme kinetic evidence, had postulated initial N-hydroxylation by the
cytochrome P450 isoform CYP1A2. This is followed by phase 2 O-conjugation and hydrolysis to form a reactive nitrenium ion that covalently binds to
DNA and produces
tumor-initiating mutations. However,
Cyp1a2(-/-) mice still possess significant liver ABP N-hydroxylation activity, DNA damage, and incidence of ABP-induced liver
tumors, and in vivo induction of
CYP1A2 paradoxically reduces levels of ABP-induced DNA damage. Competing ABP detoxification pathways can include N-acetylation by
arylamine N-acetyltransferase 1 (NAT1) and/or NAT2; however, wild-type and Nat1/2(-/-) mice have similar in vivo ABP clearance rates. Together, these studies suggest the existence of novel ABP bioactivating and clearance/detoxification
enzymes. In the present study, we detected similar reductions in Vmax for ABP N-hydroxylation by liver microsomes from
Cyp1a2(-/-) and
Cyp2e1(-/-) mice when compared with wild-type mice. In addition, recombinant mouse
CYP1A2 and
CYP2E1 were both able to N-hydroxylate ABP in mouse
hepatoma cells. However, the in vivo clearance of ABP was significantly reduced in
Cyp1a2(-/-) but not in
Cyp2e1(-/-) mice. Our results support a significant role for
CYP2E1 as a novel ABP N-oxidizing
enzyme in adult mice, and suggest a more important contribution of
CYP1A2 to the in vivo plasma clearance and thus detoxification of ABP.